According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



# **Grazoprevir Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.3
 28.09.2024
 9372510-00008
 Date of first issue: 27.08.2021

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Grazoprevir Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-

stance/Mixture

: Pharmaceutical

Recommended restrictions

on use

Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD

120 Moorgate

EC2M 6UR London, United Kingdom

Telephone : +44 (0) 2081548000

E-mail address of person

responsible for the SDS

: EHSDATASTEWARD@msd.com

### 1.4 Emergency telephone number

1-908-423-6000

### **SECTION 2: Hazards identification**

### 2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)

Specific target organ toxicity - repeated exposure, Category 2

H373: May cause damage to organs through pro-

longed or repeated exposure.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)

Hazard pictograms

Signal word : Warning

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



# **Grazoprevir Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.3
 28.09.2024
 9372510-00008
 Date of first issue: 27.08.2021

Hazard statements : H373 May cause damage to organs through prolonged

or repeated exposure.

Precautionary statements : Prevention:

P260 Do not breathe dust.

Response:

P314 Get medical advice/ attention if you feel unwell.

Hazardous components which must be listed on the label:

Grazoprevir

#### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.

May form explosive dust-air mixture during processing, handling or other means.

### **SECTION 3: Composition/information on ingredients**

# 3.2 Mixtures

#### Components

Chemical name	CAS-No. EC-No. Index-No.	Classification	Concentration (% w/w)
	Registration number		
Grazoprevir	1350462-55-3	STOT RE 2; H373 (Liver, Testis)	>= 10 - < 20
Sodium n-dodecyl sulfate	151-21-3 205-788-1	Acute Tox. 4; H302 Skin Irrit. 2; H315 Eye Dam. 1; H318 Aquatic Chronic 3; H412 ————————————————————————————————————	>= 1 - < 2.5

For explanation of abbreviations see section 16.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



# **Grazoprevir Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.3
 28.09.2024
 9372510-00008
 Date of first issue: 27.08.2021

#### **SECTION 4: First aid measures**

#### 4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.

Get medical attention if symptoms occur.

In case of skin contact : In case of contact, immediately flush skin with plenty of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting.

Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

# 4.2 Most important symptoms and effects, both acute and delayed

Symptoms : Headache

Gastrointestinal discomfort

Risks : May cause damage to organs through prolonged or repeated

exposure.

Dust contact with the eyes can lead to mechanical irritation.

#### 4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

### **SECTION 5: Firefighting measures**

#### 5.1 Extinguishing media

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing : None known.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



# **Grazoprevir Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.3
 28.09.2024
 9372510-00008
 Date of first issue: 27.08.2021

media

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides

Nitrogen oxides (NOx)

Metal oxides

Chlorine compounds Sulphur oxides

5.3 Advice for firefighters

Special protective equipment :

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

#### **SECTION 6: Accidental release measures**

### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

If spillage enters rivers or watercourses, inform the Environment Agency (emergency telephone number 0800 807060).

#### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable con-

tainer for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



# **Grazoprevir Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.3
 28.09.2024
 9372510-00008
 Date of first issue: 27.08.2021

employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

#### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

### **SECTION 7: Handling and storage**

#### 7.1 Precautions for safe handling

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation : Use only with adequate ventilation. Advice on safe handling : Do not get on skin or clothing.

Do not breathe dust. Do not swallow.

Avoid contact with eyes.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

#### 7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

Keep in properly labelled containers. Store in accordance with

the particular national regulations.

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents

7.3 Specific end use(s)

Specific use(s) : No data available

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



# **Grazoprevir Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.3
 28.09.2024
 9372510-00008
 Date of first issue: 27.08.2021

# **SECTION 8: Exposure controls/personal protection**

### 8.1 Control parameters

# **Occupational Exposure Limits**

dust of any kind 10 mg/m3

Value type (Form of exposure): TWA (Inhalable)

Basis: GB EH40

4 mg/m3

Value type (Form of exposure): TWA (Respirable fraction)

Basis: GB EH40

Components	CAS-No.	Value type (Form	Control parameters	Basis
		of exposure)		
Grazoprevir	1350462- 55-3	TWA	85 μg/m3 (OEB 3)	Internal
		Wipe limit	850 µg/100 cm <sup>2</sup>	Internal

### **Derived No Effect Level (DNEL)**

Substance name	End Use	Exposure routes	Potential health effects	Value
Sodium chloride	Workers	Inhalation	Long-term systemic effects	2068.62 mg/m3
	Workers	Inhalation	Acute systemic effects	2068.62 mg/m3
	Workers	Skin contact	Long-term systemic effects	295.52 mg/kg bw/day
	Workers	Skin contact	Acute systemic effects	295.52 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	443.28 mg/m3
	Consumers	Inhalation	Acute systemic effects	443.28 mg/m3
	Consumers	Skin contact	Long-term systemic effects	126.65 mg/kg bw/day
	Consumers	Skin contact	Acute systemic effects	126.65 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	126.65 mg/kg bw/day
	Consumers	Ingestion	Acute systemic effects	126.65 mg/kg bw/day
Sodium n-dodecyl sulfate	Workers	Inhalation	Long-term systemic effects	285 mg/m3
	Workers	Skin contact	Long-term systemic effects	4060 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	85 mg/m3
	Consumers	Skin contact	Long-term systemic effects	2440 mg/kg bw/day

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



# **Grazoprevir Formulation**

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 4.3 28.09.2024 9372510-00008 Date of first issue: 27.08.2021

Consumers Ingestion Long-term systemic 24 mg/kg effects bw/day

### **Predicted No Effect Concentration (PNEC)**

Substance name	Environmental Compartment	Value
Sodium chloride	Fresh water	5 mg/l
	Sewage treatment plant	500 mg/l
	Soil	4.86 mg/kg dry weight (d.w.)
Sodium n-dodecyl sulfate	Fresh water	0.176 mg/l
	Marine water	0.018 mg/l
	Sewage treatment plant	1.35 mg/l
	Fresh water sediment	6.97 mg/kg dry weight (d.w.)
	Marine sediment	0.697 mg/kg dry weight (d.w.)
	Soil	1.29 mg/kg dry weight (d.w.)

### 8.2 Exposure controls

### **Engineering measures**

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable

suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Equipment should conform to BS EN 143

Filter type : Particulates type (P)

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



# **Grazoprevir Formulation**

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 4.3 28.09.2024 9372510-00008 Date of first issue: 27.08.2021

#### **SECTION 9: Physical and chemical properties**

9.1 Information on basic physical and chemical properties

Appearance : powder

Colour : No data available
Odour : No data available
Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : Not applicable

Evaporation rate : Not applicable

Flammability (solid, gas) : May form explosive dust-air mixture during processing, han-

dling or other means.

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower :

flammability limit

No data available

Vapour pressure : Not applicable

Relative vapour density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available Partition coefficient: n- : Not applicable

octanol/water

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

#### 9.2 Other information

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



# **Grazoprevir Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.3
 28.09.2024
 9372510-00008
 Date of first issue: 27.08.2021

Flammability (liquids) : No data available

Particle size : No data available

### **SECTION 10: Stability and reactivity**

### 10.1 Reactivity

Not classified as a reactivity hazard.

#### 10.2 Chemical stability

Stable under normal conditions.

#### 10.3 Possibility of hazardous reactions

Hazardous reactions : May form explosive dust-air mixture during processing, han-

dling or other means.

Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

### **SECTION 11: Toxicological information**

#### 11.1 Information on toxicological effects

Information on likely routes of : Inhalation exposure Skin contact

Ingestion
Eye contact

#### **Acute toxicity**

Not classified based on available information.

**Product:** 

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg

Method: Calculation method

**Components:** 

**Grazoprevir:** 

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

Sodium n-dodecyl sulfate:

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



# **Grazoprevir Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.3
 28.09.2024
 9372510-00008
 Date of first issue: 27.08.2021

Acute oral toxicity : LD50 (Rat): 1,200 mg/kg

Method: OECD Test Guideline 401

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg

Method: OECD Test Guideline 402

Remarks: Based on data from similar materials

#### Skin corrosion/irritation

Not classified based on available information.

#### **Components:**

#### Grazoprevir:

Result : No skin irritation

#### Sodium n-dodecyl sulfate:

Species : Rabbit Result : Skin irritation

#### Serious eye damage/eye irritation

Not classified based on available information.

#### **Components:**

### **Grazoprevir:**

Species : Bovine cornea Result : No eye irritation

#### Sodium n-dodecyl sulfate:

Species : Rabbit

Method : OECD Test Guideline 405
Result : Irreversible effects on the eye

#### Respiratory or skin sensitisation

#### Skin sensitisation

Not classified based on available information.

#### Respiratory sensitisation

Not classified based on available information.

#### **Components:**

#### **Grazoprevir:**

Test Type : Local lymph node assay (LLNA)

Exposure routes : Dermal

Result : Not a skin sensitizer.

# Sodium n-dodecyl sulfate:

Test Type : Maximisation Test

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



# **Grazoprevir Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.3
 28.09.2024
 9372510-00008
 Date of first issue: 27.08.2021

Exposure routes : Skin contact
Species : Guinea pig
Result : negative

Remarks : Based on data from similar materials

Germ cell mutagenicity

Not classified based on available information.

**Components:** 

Grazoprevir:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test

Application Route: Oral

Result: negative

Germ cell mutagenicity- As-

sessment

Weight of evidence does not support classification as a germ

cell mutagen.

Sodium n-dodecyl sulfate:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Method: OECD Test Guideline 471

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Genotoxicity in vivo : Test Type: Rodent dominant lethal test (germ cell) (in vivo)

Species: Mouse

Application Route: Ingestion

Result: negative

Carcinogenicity

Not classified based on available information.

**Components:** 

Sodium n-dodecyl sulfate:

Species : Rat
Application Route : Ingestion
Exposure time : 2 Years

Method : OECD Test Guideline 453

Result : negative

Remarks : Based on data from similar materials

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



# **Grazoprevir Formulation**

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 4.3 28.09.2024 9372510-00008 Date of first issue: 27.08.2021

#### Reproductive toxicity

Not classified based on available information.

#### **Components:**

**Grazoprevir:** 

Effects on fertility : Test Type: Fertility

Species: Rat

Application Route: Oral

Fertility: NOAEL: 400 mg/kg body weight

Result: negative

Test Type: Multi-generation study

Species: Rat

Application Route: Oral

Fertility: NOAEL: 400 mg/kg body weight

Result: No effects on fertility, No effects on foetal development

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Oral

Embryo-foetal toxicity: NOAEL: 200 mg/kg body weight

Result: No effects on foetal development

Test Type: Embryo-foetal development

Species: Rabbit Application Route: Oral

Embryo-foetal toxicity: NOAEL: 200 mg/kg body weight

Result: No effects on foetal development

Test Type: Embryo-foetal development

Species: Rabbit

Application Route: Intravenous

Embryo-foetal toxicity: NOAEL: 100 mg/kg body weight

Result: No effects on foetal development

Sodium n-dodecyl sulfate:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion Method: OECD Test Guideline 416

Result: negative

Remarks: Based on data from similar materials

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Ingestion

Result: negative

Remarks: Based on data from similar materials

### STOT - single exposure

Not classified based on available information.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



# **Grazoprevir Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.3
 28.09.2024
 9372510-00008
 Date of first issue: 27.08.2021

#### STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

#### **Components:**

#### **Grazoprevir:**

Target Organs : Liver, Testis

Assessment : May cause damage to organs through prolonged or repeated

exposure.

#### Repeated dose toxicity

#### Components:

### Grazoprevir:

Species : Rat

NOAEL : 400 mg/kg Application Route : Oral Exposure time : 30 Days

Remarks : No significant adverse effects were reported

Species : Rat
NOAEL : 400 mg/kg

Application Route : Oral
Exposure time : 180 Days

Remarks : No significant adverse effects were reported

Species : Dog
NOAEL : 15 mg/kg
LOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 270 Days

Target Organs : Liver, Blood, Bone marrow, gallbladder, spleen, Testis

Species : Mouse
NOAEL : 200 mg/kg
LOAEL : 500 mg/kg
Application Route : Oral
Exposure time : 90 Days

Target Organs : Liver, Kidney, Blood

Species : Dog
NOAEL : 20 mg/kg
LOAEL : 600 mg/kg
Application Route : Oral
Exposure time : 30 Days
Target Organs : Blood, Testis

Species : Monkey NOAEL : 10 mg/kg Exposure time : 8 Days

Remarks : No significant adverse effects were reported

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



# **Grazoprevir Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.3
 28.09.2024
 9372510-00008
 Date of first issue: 27.08.2021

Sodium n-dodecyl sulfate:

Species : Rat
NOAEL : 488 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Remarks : Based on data from similar materials

**Aspiration toxicity** 

Not classified based on available information.

**Experience with human exposure** 

**Components:** 

Grazoprevir:

Ingestion : Symptoms: Headache, Gastrointestinal disturbance

#### **SECTION 12: Ecological information**

#### 12.1 Toxicity

#### **Components:**

**Grazoprevir:** 

Toxicity to fish : LC50 (Cyprinodon variegatus (sheepshead minnow)): > 10

mg/l

Exposure time: 96 h

Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 10 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Remarks: No toxicity at the limit of solubility

LC50 (Americamysis): 8.9 mg/l

Exposure time: 96 h

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 10

mg/I

Exposure time: 72 hrs

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

NOEC (Pseudokirchneriella subcapitata (green algae)): 10

mq/l

Exposure time: 72 hrs

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms : EC50 : > 1,000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



# **Grazoprevir Formulation**

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 4.3 28.09.2024 9372510-00008 Date of first issue: 27.08.2021

Method: OECD Test Guideline 209

NOEC: 1.3 mg/l Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Toxicity to fish (Chronic tox-

icity)

NOEC: 0.98 mg/l Exposure time: 32 d

Species: Pimephales promelas (fathead minnow)

Method: OECD Test Guideline 210

Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC: 5 mg/l Exposure time: 21 d

Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

Sodium n-dodecyl sulfate:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 29 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Ceriodaphnia dubia (water flea)): 5.55 mg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

ErC50 (Desmodesmus subspicatus (green algae)): > 120 mg/l

Exposure time: 72 h

NOEC (Desmodesmus subspicatus (green algae)): 30 mg/l

Exposure time: 72 h

Toxicity to microorganisms : EC50 : 135 mg/l

Exposure time: 3 h

Toxicity to fish (Chronic tox-

icity)

NOEC: >= 1.357 mg/l Exposure time: 42 d

Species: Pimephales promelas (fathead minnow)

Toxicity to daphnia and other :

aquatic invertebrates (Chron-

NOEC: 0.88 mg/l Exposure time: 7 d

ic toxicity)

Species: Ceriodaphnia dubia (water flea)

### 12.2 Persistence and degradability

### **Components:**

Grazoprevir:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 66 % Exposure time: 28 d

#### Sodium n-dodecyl sulfate:

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



# **Grazoprevir Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.3
 28.09.2024
 9372510-00008
 Date of first issue: 27.08.2021

Biodegradability : Result: Readily biodegradable.

Biodegradation: 95 % Exposure time: 28 d

Method: OECD Test Guideline 301B

#### 12.3 Bioaccumulative potential

**Components:** 

Grazoprevir:

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)

Bioconcentration factor (BCF): 7.62

Partition coefficient: n-

octanol/water

log Pow: 3.72

Sodium n-dodecyl sulfate:

Partition coefficient: n-

octanol/water

log Pow: 0.83

12.4 Mobility in soil

**Components:** 

Grazoprevir:

Distribution among environ-

mental compartments

: log Koc: 4.01

12.5 Results of PBT and vPvB assessment

**Product:** 

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

12.6 Other adverse effects

Product:

Endocrine disrupting poten-

tial

This substance/mixture does not contain components considered to have endocrine disrupting properties for environment

according to UK REACH Article 57(f).

**SECTION 13: Disposal considerations** 

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Do not dispose of waste into sewer.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



# **Grazoprevir Formulation**

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 4.3 28.09.2024 9372510-00008 Date of first issue: 27.08.2021

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

#### **SECTION 14: Transport information**

#### 14.1 UN number

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.2 UN proper shipping name

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

# 14.3 Transport hazard class(es)

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

#### 14.4 Packing group

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA (Cargo) : Not regulated as a dangerous good
IATA (Passenger) : Not regulated as a dangerous good

#### 14.5 Environmental hazards

Not regulated as a dangerous good

#### 14.6 Special precautions for user

Not applicable

#### 14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



# **Grazoprevir Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.3
 28.09.2024
 9372510-00008
 Date of first issue: 27.08.2021

### **SECTION 15: Regulatory information**

# 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Relevant EU provisions transposed through retained EU law

UK REACH List of restrictions (Annex 17) : Not applicable

UK REACH Candidate list of substances of very high : Not applicable

concern (SVHC) for Authorisation

The Persistent Organic Pollutants Regulations (retained : Not applicable

Regulation (EU) 2019/1021 as amended for Great Brit-

ain)

Regulation (EC) on substances that deplete the ozone : Not applicable

layer

UK REACH List of substances subject to authorisation : Not applicable

(Annex XIV)

GB Export and import of hazardous chemicals - Prior : Not applicable

Informed Consent (PIC) Regulation

Control of Major Accident Hazards Regulations 2015 (COMAH)

Not applicable

#### Other regulations:

Take note of The Management of Health and Safety at Work Regulations 1999 (requirements relating to protection of young people at work contained in Regulation 19) and of Directive 94/33/EC on the protection of young people at work.

#### The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

#### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

#### **SECTION 16: Other information**

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

**Full text of H-Statements** 

H302 : Harmful if swallowed. H315 : Causes skin irritation.

H318 : Causes serious eye damage.

H373 : May cause damage to organs through prolonged or repeated

exposure if swallowed.

H412 : Harmful to aquatic life with long lasting effects.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



# **Grazoprevir Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.3
 28.09.2024
 9372510-00008
 Date of first issue: 27.08.2021

#### Full text of other abbreviations

Acute Tox. : Acute toxicity

Aquatic Chronic : Long-term (chronic) aquatic hazard

Eye Dam. : Serious eye damage

Skin Irrit. : Skin irritation

STOT RE : Specific target organ toxicity - repeated exposure GB EH40 : UK. EH40 WEL - Workplace Exposure Limits

GB EH40 / TWA : Long-term exposure limit (8-hour TWA reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice: IARC - International Agency for Research on Cancer: IATA - International Air Transport Association: IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods: vPvB - Very Persistent and Very Bioaccumulative

#### **Further information**

Sheet

Sources of key data used to compile the Safety Data

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Classification of the mixture:

Classification procedure:

STOT RE 2 H373 Calculation method

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



# **Grazoprevir Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.3
 28.09.2024
 9372510-00008
 Date of first issue: 27.08.2021

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

GB / EN